Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetrelimab in Chronic Hepatitis B
NCT05242445Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2022
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of cetrelimab in Chronic Hepatitis B (CHB) (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Serum Concentration up to 24 weeks, Area Under the Concentration-time Curve up to 24 weeks and 2 more. Started Apr 2022; status: completed.
02
Drugs
cetrelimab
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05242445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05242445.